EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes

Tongjia Zhang, Shujie Wang, Yue Zhou, Zitao Jiao, Kejia Lu, Xinyi Liu, Hui Li, Wei Jiang, Xiaowei Zhang iD

PLOS Biology · 2025

DOI: 10.1371/journal.pbio.3002846 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Biology, 2025. Verfasst von Tongjia Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Beijing Key Laboratory of Protein Posttranslational Modifications…. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Alternative Splicing, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation, Beijing Natural Science Foundation Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Indisulam, a sulfonamide-based compound, is employed as a second-line therapy for NSCLC due to its anti-tumor activity. However, its clinical efficacy is hindered by acquired resistance, the molecular basis of which remains poorly understood. Here, we demonstrate that hypermethylation of RNA-binding protein 39 (RBM39), a specific target of Indisulam, is closely associated with Indisulam resistance. PRMT6 methylates RBM39 at R92. This methylation inhibits Indisulam-induced ubiquitination and proteasomal degradation of RBM39, increases RBM39 protein levels, promotes alternative splicing and expression of proto-oncogenes, and ultimately leads to malignant proliferation and metastasis of NSCLC cells and tumor growth in xenograft mouse models. Inhibiting PRMT6 with MS023 or mutating the RBM39 methylation site enhances Indisulam sensitivity in NSCLC and significantly improves its anti-tumor efficacy. Our findings identify methylated RBM39 as a key biomarker of Indisulam resistance and suggest a potential therapeutic strategy for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA-Binding ProteinsAlternative SplicingCarcinoma, Non-Small-Cell LungLung NeoplasmsProtein-Arginine N-MethyltransferasesDrug Resistance, NeoplasmHumansAnimalsMiceMethylationCell Line, TumorCell ProliferationXenograft Model Antitumor AssaysGene Expression Regulation, NeoplasticMice, NudeDNA MethylationNuclear Proteins

Substanzen

RNA-Binding ProteinsProtein-Arginine N-MethyltransferasesPRMT6 protein, humanNuclear Proteins

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, Peking University Health Science Center, Beijing,…

ORCID-Profile: Xiaowei Zhang

Förderung

  • National Natural Science Foundation of China
  • Beijing Natural Science Foundation
  • Beijing Natural Science Foundation Grant

Zitieren

APA

Zhang, T., Wang, S., Zhou, Y., Jiao, Z., Lu, K., Liu, X., Li, H., Jiang, W., & Zhang, X. (2025). Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes. PLOS Biology. https://doi.org/10.1371/journal.pbio.3002846

Vancouver

Zhang T, Wang S, Zhou Y, Jiao Z, Lu K, Liu X, et al. Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes. PLOS Biology. 2025. doi:10.1371/journal.pbio.3002846

BibTeX
@article{Zhang2025,
  author = {Zhang, Tongjia and Wang, Shujie and Zhou, Yue and Jiao, Zitao and Lu, Kejia and Liu, Xinyi and Li, Hui and Jiang, Wei and Zhang, Xiaowei},
  title = {Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes},
  journal = {PLOS Biology},
  year = {2025},
  doi = {10.1371/journal.pbio.3002846}
}
Kostenlos starten →